{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:01:58Z","timestamp":1782367318238,"version":"3.54.5"},"reference-count":102,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"am","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.therap.2023.10.010","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:59:56Z","timestamp":1698793196000},"page":"271-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Drug-induced glomerular diseases"],"prefix":"10.1016","volume":"79","author":[{"given":"Anne-Sophie","family":"Garnier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Laubacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Briet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.10.010_bib0515","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.10.010_bib0520","doi-asserted-by":"crossref","first-page":"899164","DOI":"10.3389\/fphar.2022.899164","article-title":"Use of the capture-recapture method to estimate the frequency of community- and hospital-acquired drug-induced acute kidney injuries in French databases","volume":"13","author":"Rey","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.therap.2023.10.010_bib0525","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/jcm10020168","article-title":"Drug-induced acute kidney injury: a study from the French medical administrative and the French national pharmacovigilance databases using capture-recapture method","volume":"10","author":"Rolland","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.therap.2023.10.010_bib0530","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00000441-200106000-00005","article-title":"Impaired renal autoregulation: implications for the genesis of hypertension and hypertension-induced renal injury","volume":"321","author":"Palmer","year":"2001","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.therap.2023.10.010_bib0535","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1440-1797.2006.00583.x","article-title":"Role of podocyte slit diaphragm as a filtration barrier","volume":"11","author":"Kawachi","year":"2006","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.therap.2023.10.010_bib0540","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","article-title":"Minimal change disease","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0545","doi-asserted-by":"crossref","first-page":"761600","DOI":"10.3389\/fmed.2021.761600","article-title":"Molecular mechanisms of proteinuria in minimal change disease","volume":"8","author":"Purohit","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.therap.2023.10.010_bib0550","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach","volume":"29","author":"De Vriese","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0555","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nrneph.2016.147","article-title":"Minimal change disease and idiopathic FSGS: manifestations of the same disease","volume":"12","author":"Maas","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0560","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000183363","article-title":"Morphological transition in minimal change nephrotic syndrome","volume":"39","author":"Tejani","year":"1985","journal-title":"Nephron"},{"key":"10.1016\/j.therap.2023.10.010_bib0565","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.ki.5002222","article-title":"The spectrum of podocytopathies: a unifying view of glomerular diseases","volume":"71","author":"Wiggins","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.therap.2023.10.010_bib0570","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.therap.2023.10.010_bib0575","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.10.010_bib0580","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.10.010_bib0585","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ki.1992.374","article-title":"Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis","volume":"42","author":"Pei","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.therap.2023.10.010_bib0590","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejim.2006.03.001","article-title":"Penicillamine and nephrotic syndrome","volume":"17","author":"Habib","year":"2006","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.therap.2023.10.010_bib0595","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/rheumatology\/25.2.193","article-title":"European League against Rheumatism study of adverse reactions to D-penicillamine","volume":"25","author":"Kay","year":"1986","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.therap.2023.10.010_bib0600","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0049-0172(86)90023-5","article-title":"Penicillamine-induced proteinuria: risk factors","volume":"15","author":"Stein","year":"1986","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.therap.2023.10.010_bib0605","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000181984","article-title":"Penicillamine nephropathy","volume":"26","author":"Ross","year":"1980","journal-title":"Nephron"},{"key":"10.1016\/j.therap.2023.10.010_bib0610","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0022-5347(17)56420-4","article-title":"Nephrotic syndrome during treatment with alpha-mercaptopropionylglycine","volume":"122","author":"Rizzoni","year":"1979","journal-title":"J Urol"},{"key":"10.1016\/j.therap.2023.10.010_bib0615","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/art.1780280526","article-title":"Nephrotic syndrome induced by tiopronin: association with the HLA-DR3 antigen","volume":"28","author":"Salvarani","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.therap.2023.10.010_bib0620","first-page":"235","article-title":"Clinical efficacy and adverse effects of tiopronin in rheumatoid arthritis. Report of a follow-up in 50 patients","volume":"41","author":"Ambanelli","year":"1982","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.therap.2023.10.010_bib0625","first-page":"105","article-title":"Long-term tolerability of tiopronin (Acadione) in the treatment of rheumatoid arthritis. Apropos of 140 personal cases","volume":"57","author":"Sany","year":"1990","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"10.1016\/j.therap.2023.10.010_bib0630","first-page":"1019","article-title":"Basic treatment of rheumatoid arthritis with tiopronin. A study of 25 cases","volume":"80","author":"Mordini","year":"1989","journal-title":"Minerva Med"},{"key":"10.1016\/j.therap.2023.10.010_bib0635","first-page":"65","article-title":"Toxicity due to remission inducing drugs in rheumatoid arthritis. Association with HLA-B35 and Cw4 antigens","volume":"13","author":"Ferraccioli","year":"1986","journal-title":"J Rheumatol"},{"key":"10.1016\/j.therap.2023.10.010_bib0640","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00467-019-04440-2","article-title":"Nephrotic syndrome in a patient with cystinuria: answers","volume":"35","author":"Aksoy","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0645","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2215\/CJN.14331218","article-title":"Risk of nephrotic syndrome for non-steroidal anti-inflammatory drug users","volume":"14","author":"Bakhriansyah","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0650","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.2215\/CJN.08090719","article-title":"NSAIDs and nephrotic syndrome","volume":"14","author":"M\u00e9rida","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0655","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jama.1996.03540060042033","article-title":"Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs","volume":"276","author":"Radford","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2023.10.010_bib0660","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5414\/CNP59137","article-title":"Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib","volume":"59","author":"Markowitz","year":"2003","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0665","first-page":"279","article-title":"Membranous nephropathy associated with the use of flurbiprofen","volume":"47","author":"MacKay","year":"1997","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0670","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000189356","article-title":"Membranous nephropathy associated with oxaprozin treatment","volume":"74","author":"Ogawa","year":"1996","journal-title":"Nephron"},{"key":"10.1016\/j.therap.2023.10.010_bib0675","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.ajkd.2013.03.045","article-title":"Membranous nephropathy and nonsteroidal anti-inflammatory agents","volume":"62","author":"Nawaz","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.therap.2023.10.010_bib0680","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.kint.2023.04.006","article-title":"Proprotein convertase subtilisin\/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.therap.2023.10.010_bib0685","doi-asserted-by":"crossref","first-page":"F1168","DOI":"10.1152\/ajprenal.00145.2016","article-title":"What we need to know about the effect of lithium on the kidney","volume":"311","author":"Gong","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.therap.2023.10.010_bib0690","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1176\/ajp.146.1.84","article-title":"Lithium-induced nephrotic syndrome","volume":"146","author":"Wood","year":"1989","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.therap.2023.10.010_bib0695","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3181\/00379727-198-43298","article-title":"Enhancement of interleukin 2 production in human and Gibbon T cells after in vitro treatment with lithium","volume":"198","author":"Wu","year":"1991","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.therap.2023.10.010_bib0700","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0272-6386(96)90108-0","article-title":"Nephrotic syndrome and renal insufficiency associated with lithium therapy","volume":"27","author":"Tam","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.therap.2023.10.010_bib0705","doi-asserted-by":"crossref","first-page":"F1152","DOI":"10.1152\/ajprenal.00373.2010","article-title":"GSK3\u03b2 inactivation in podocytes results in decreased phosphorylation of p70S6K accompanied by cytoskeletal rearrangements and inhibited motility","volume":"300","author":"George","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.therap.2023.10.010_bib0710","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.ajpath.2014.06.027","article-title":"Glycogen synthase kinase 3\u03b2 dictates podocyte motility and focal adhesion turnover by modulating paxillin activity: implications for the protective effect of low-dose lithium in podocytopathy","volume":"184","author":"Xu","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.therap.2023.10.010_bib0715","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2215\/CJN.07571009","article-title":"Mercury-induced membranous nephropathy: clinical and pathological features","volume":"5","author":"Li","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0720","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1053\/j.ajkd.2013.02.372","article-title":"Mercury-associated nephrotic syndrome: a case report and systematic review of the literature","volume":"62","author":"Miller","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.therap.2023.10.010_bib0725","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0730","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/ndt\/gfg567","article-title":"Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient","volume":"19","author":"Kunin","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.therap.2023.10.010_bib0735","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1523-1755.2004.00426.x","article-title":"Podocyte injury associated glomerulopathies induced by pamidronate","volume":"65","author":"Barri","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.therap.2023.10.010_bib0740","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1093\/ndt\/gfm209","article-title":"Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient","volume":"22","author":"Bodmer","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.therap.2023.10.010_bib0745","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00198-011-1836-2","article-title":"Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis","volume":"23","author":"Yilmaz","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.therap.2023.10.010_bib0750","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2169\/internalmedicine.52.0094","article-title":"Acute kidney injury in a patient with nephrotic syndrome due to focal segmental glomerular nephritis induced by a single oral administration of high-dose bisphosphonate (minodronate)","volume":"52","author":"Komada","year":"2013","journal-title":"Intern Med"},{"key":"10.1016\/j.therap.2023.10.010_bib0755","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/ajkd.2002.32797","article-title":"Nephrotic syndrome after treatment with pamidronate","volume":"39","author":"Markowitz","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.therap.2023.10.010_bib0760","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.therap.2023.10.010_bib0765","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0770","doi-asserted-by":"crossref","first-page":"F1656","DOI":"10.1152\/ajprenal.00275.2009","article-title":"The balance of autocrine VEGF-A and VEGF-C determines podocyte survival","volume":"297","author":"M\u00fcller-Deile","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.therap.2023.10.010_bib0775","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.therap.2023.10.010_bib0780","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1172\/JCI119416","article-title":"Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis","volume":"99","author":"Kitamoto","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.therap.2023.10.010_bib0785","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ki.2010.64","article-title":"Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease","volume":"77","author":"Veron","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.therap.2023.10.010_bib0790","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.344","article-title":"Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy","volume":"85","author":"Izzedine","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.therap.2023.10.010_bib0795","doi-asserted-by":"crossref","first-page":"ra39","DOI":"10.1126\/scisignal.2000678","article-title":"c-mip impairs podocyte proximal signaling and induces heavy proteinuria","volume":"3","author":"Zhang","year":"2010","journal-title":"Sci Signal"},{"key":"10.1016\/j.therap.2023.10.010_bib0800","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.therap.2023.10.010_bib0805","doi-asserted-by":"crossref","first-page":"579603","DOI":"10.3389\/fmed.2020.579603","article-title":"Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors VEGF blockade-related TMA after intravitreal use","volume":"7","author":"Hanna","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.therap.2023.10.010_bib0810","first-page":"2919080","article-title":"Intravitreal injection of anti-VEGF antibody induces glomerular endothelial cells injury","volume":"2019","author":"Touzani","year":"2019","journal-title":"Case Rep Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0815","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1097\/TP.0000000000000750","article-title":"Intravitreal antivascular endothelial growth factor therapy may induce proteinuria and antibody mediated injury in renal allografts","volume":"99","author":"Cheungpasitporn","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.therap.2023.10.010_bib0820","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/j.ajkd.2010.11.030","article-title":"Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors","volume":"57","author":"Pell\u00e9","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.therap.2023.10.010_bib0825","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ckj\/sfy060","article-title":"Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension","volume":"12","author":"Hanna","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.therap.2023.10.010_bib0830","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.therap.2023.10.010_bib0835","doi-asserted-by":"crossref","first-page":"1100397","DOI":"10.3389\/fmed.2023.1100397","article-title":"Do intravitreal anti-vascular endothelial growth factor agents lead to renal adverse events? A pharmacovigilance real-world study","volume":"10","author":"Jiang","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.therap.2023.10.010_bib0840","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s13730-020-00558-7","article-title":"Minimal change disease concurrent with acute interstitial nephritis after long-term use of sorafenib in a patient with renal cell carcinoma","volume":"10","author":"Ihara","year":"2021","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.therap.2023.10.010_bib0845","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1016\/j.transproceed.2018.07.020","article-title":"Development of focal segmental glomerulosclerosis and thrombotic microangiopathy in a liver transplant patient on sorafenib for hepatocellular carcinoma: a case report","volume":"50","author":"Hanna","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.therap.2023.10.010_bib0850","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2215\/CJN.03751106","article-title":"High sirolimus levels may induce focal segmental glomerulosclerosis de novo","volume":"2","author":"Letavernier","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0855","doi-asserted-by":"crossref","first-page":"e99271","DOI":"10.1172\/jci.insight.99271","article-title":"mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans","volume":"4","author":"Puelles","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.therap.2023.10.010_bib0860","first-page":"371","volume":"26","author":"Manabe","year":"2021","journal-title":"Everolimus-associated focal segmental glomerulosclerosis in a liver transplant recipient. Nephrology (Carlton)"},{"key":"10.1016\/j.therap.2023.10.010_bib0865","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000201930","article-title":"Temsirolimus-induced glomerulopathy","volume":"76","author":"Izzedine","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.therap.2023.10.010_bib0870","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s13730-021-00622-w","article-title":"Focal segmental glomerulosclerosis and concurrent glomerular microangiopathy after long-term imatinib administration","volume":"11","author":"Morita","year":"2022","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.therap.2023.10.010_bib0875","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/s41467-019-09936-x","article-title":"Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity","volume":"10","author":"Calizo","year":"2019","journal-title":"Nat Commun"},{"issue":"4 Pt 2","key":"10.1016\/j.therap.2023.10.010_bib0880","first-page":"F553","article-title":"Segmental distribution of epidermal growth factor binding sites in rabbit nephron","volume":"259","author":"Breyer","year":"1990","journal-title":"Am J Physiol"},{"key":"10.1016\/j.therap.2023.10.010_bib0885","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1007\/s13277-014-2983-9","article-title":"Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials","volume":"36","author":"Wang","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.therap.2023.10.010_bib0890","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(07)70108-0","article-title":"Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study","volume":"8","author":"Tejpar","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.therap.2023.10.010_bib0895","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1681\/ASN.2008030327","article-title":"EGF increases TRPM6 activity and surface expression","volume":"20","author":"Thebault","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0900","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1681\/ASN.2009111153","article-title":"Effects of the EGFR Inhibitor erlotinib on magnesium handling","volume":"21","author":"Dimke","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib0905","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2169\/internalmedicine.54.3661","article-title":"Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib","volume":"54","author":"Maruyama","year":"2015","journal-title":"Intern Med"},{"key":"10.1016\/j.therap.2023.10.010_bib0910","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.3390\/cancers13235907","article-title":"Renal safety profile of EGFR targeted therapies: a study from VigiBase\u00ae the WHO global database of individual case safety reports","volume":"13","author":"Crosnier","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.therap.2023.10.010_bib0915","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis","volume":"7","author":"Xing","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.therap.2023.10.010_bib0920","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.therap.2023.10.010_bib0925","doi-asserted-by":"crossref","first-page":"e000467","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.therap.2023.10.010_bib0930","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.therap.2023.10.010_bib0935","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1007\/s00262-021-02983-8","article-title":"Immune checkpoint inhibitors-induced nephropathy: a French national survey","volume":"70","author":"G\u00e9rard","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.therap.2023.10.010_bib0940","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.therap.2023.10.010_bib0945","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic syndrome with cancer immunotherapies: a\u00a0report\u00a0of\u00a02 cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.therap.2023.10.010_bib0950","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","article-title":"Ipilimumab-associated minimal-change disease","volume":"89","author":"Kidd","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.therap.2023.10.010_bib0955","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.therap.2023.10.010_bib0960","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2018.05.015","article-title":"Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: an autopsy case report","volume":"122","author":"Takahashi","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.therap.2023.10.010_bib0965","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.10.010_bib0970","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.therap.2023.10.010_bib0975","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","article-title":"Immune checkpoint inhibitors and immune-related adverse renal events","volume":"5","author":"Herrmann","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.therap.2023.10.010_bib0980","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.therap.2023.10.010_bib0985","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1053\/j.ajkd.2003.10.024","article-title":"Pathologic classification of focal segmental glomerulosclerosis: a working proposal","volume":"43","author":"D\u2019Agati","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.therap.2023.10.010_bib0990","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s40425-019-0655-4","article-title":"Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy","volume":"7","author":"Glutsch","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.therap.2023.10.010_bib0995","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1002\/cnr2.1250","article-title":"Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity?","volume":"3","author":"Vaughan","year":"2020","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.therap.2023.10.010_bib1000","first-page":"1264","article-title":"Drug-induced podocytopathies: report of four cases and review of the literature","volume":"13","author":"Athanasopoulou","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.therap.2023.10.010_bib1005","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1186\/s12885-016-2718-y","article-title":"Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma","volume":"16","author":"Bickel","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.therap.2023.10.010_bib1010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","article-title":"Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report","volume":"40","author":"Daanen","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.therap.2023.10.010_bib1015","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12882-018-0958-6","article-title":"Minimal change disease associated with anti-PD1 immunotherapy: a case report","volume":"19","author":"Gao","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.therap.2023.10.010_bib1020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2019.12.015","article-title":"Re-administration of pembrolizumab with prednisolone after pembrolizumab-induced nephrotic syndrome","volume":"126","author":"Saito","year":"2020","journal-title":"Eur J Cancer"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T19:59:08Z","timestamp":1711655948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723001762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":102,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0040595723001762"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.10.010","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced glomerular diseases","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}